查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827996

自動胰島素輸送系統市場按產品類型、組件、胰島素類型、技術、糖尿病類型、治療環境、最終用戶和分銷管道分類 - 全球預測 2025-2032

Automated Insulin Delivery System Market by Product Type, Component, Insulin Type, Technology, Diabetes Type, Care Setting, End User, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，自動胰島素輸送系統市場將成長至 19.4207 億美元，複合年成長率為 10.07%。

主要市場統計數據
基準年2024年 9.0104億美元
預計2025年 9.9029億美元
預測年份：2032年 1,942,070,000美元
複合年成長率（%） 10.07%

全面介紹整合感測、先進控制演算法和設備人體工學如何重新定義自動胰島素輸送的臨床和商業性期望

自動胰島素輸送系統正在再形成糖尿病管理，它整合了持續血糖監測、自適應控制演算法和自動胰島素輸送，以減輕日常負擔並改善血糖穩定性。最近幾代設備已從組件級改進邁向系統級改進，將感測器保真度、演算法複雜性和泵浦人體工學融為一體，打造出一種能夠動態響應生理波動的閉合迴路體驗。這一發展軌跡反映了數十年來技術創新的不斷進步和數位醫療應用的加速發展。

臨床醫生和醫療系統擴大評估這些平台，不再僅僅基於單一指標，而是關注它們如何影響以患者為中心的治療結果、工作流程整合和長期依從性。同時，軟體主導控制策略的進步使得血糖值軌跡更加平滑，並增加了更多觸點，從而支援遠端醫療。因此，產品差異化正從機械致動器效能轉向互通性、使用者體驗設計和資料安全性。

總的來說，這些發展將圍繞自動化醫療保健的討論從純粹的工程挑戰擴展到多學科實施挑戰，要求相關人員將臨床通訊協定、報銷途徑、患者教育和不斷發展的法規環境作為任何部署戰略的核心要素。

技術、法規和使用者體驗的融合正在加速胰島素自動輸送領域的發展

在技​​術、臨床和商業性力量融合的推動下，胰島素自動給藥領域正在經歷一場變革性的轉變。持續血糖監測技術的進步提高了訊號穩定性並縮短了滯後時間，使控制演算法能夠做出更可靠的給藥決策。同時，演算法方法也正在從基於規則的啟發式演算法發展到預測性和自適應模型，這些模型融合了飲食行為、運動、壓力反應等變數。這種演變使得個別患者層面的個人化治療成為可能，同時提高了安全裕度。

在商業方面，使用者體驗設計和外形尺寸的創新正在透過解決諸如設備可見性、插入不適感和設備維護負擔等依從性障礙來提升其應用。互通性框架和開放通訊協定舉措正在推動模組化生態系統的形成，在該生態系統中，泵浦、感測器和軟體可以以新的配置進行組合。同時，監管機構正在製定清晰的軟體和演算法更新路徑，以支援初始核准後的迭代改進週期。總的來說，這些轉變正在推動該領域從推出孤立的產品轉向協調生態系統，在這個生態系統中，臨床結果、病患滿意度和營運整合將決定長期成功。

從策略角度考慮 2025 年美國關稅制度生效對營運和供應鏈造成的累積影響，以及相關人員如何適應

2025年美國推出的新關稅和貿易政策，對涉及自動胰島素輸送系統的製造商、經銷商和醫療保健採購商產生了具體的營運和策略影響。雖然關稅通常表現為硬體組件和成品到岸成本的增加，但其更廣泛的影響可能會透過供應鏈設計、採購決策和產品藍圖層層遞進。擁有精益、地理集中的供應鏈的企業將更容易受到成本波動的影響，而擁有多元化籌資策略的企業將能夠保護利潤率並保持定價彈性。

從採購角度來看，關稅將鼓勵近岸外包和供應商本地化，尤其是在感測器材料、控制電子設備中使用的半導體晶片以及專用泵的致動器等關鍵部件方面。這種轉變可能會改變供應商的談判動態，並加速對本地製造能力、認證和品質保證流程的投資。監管和採購團隊還必須預測供應商評估標準的變化，包括總到岸成本、前置作業時間的可靠性以及對未來貿易政策變化的適應能力。

如果製造商為了應對成本壓力而推遲非必需產品的發布，臨床醫生和醫療系統在某些領域可能會經歷產品更新周期的放緩。同時，以軟體為中心、所需實體投入較少的功能可能會成為一種經濟高效的產品差異化方式，從而獲得相對突出的優勢。總體而言，關稅環境將重新定義策略重點，使其轉向供應鏈彈性、模組化產品架構以及能夠降低貿易中斷風險的合作。

全面的基於細分的洞察將產品架構、組件選擇、胰島素配方、連接標準、護理環境、分銷策略等連結到可操作的商業智慧中

我們深入的細分揭示了產品設計選擇和最終用途環境如何影響自動化胰島素輸送系統的臨床價值提案和商業化策略。根據產品類型，平台範圍從旨在最大程度減少手動輸入的全閉合迴路系統，到將自動基礎劑量調整與用戶主導Bolus相結合的混合閉合迴路配置。在混合解決方案中，控制方法包括模糊邏輯、模型預測控制和比例-積分-微分技術，每種方法在響應性和穩定性之間提供不同的權衡。在特定的臨床領域，感測器驅動幫浦和閾值暫停幫浦仍然具有相關性，因為成本、熟悉度或監管限制會影響選擇。

組件級差異進一步明確了功能和整合路徑。連續血糖監測儀提供瞬時監測或即時遙測，控制演算法軟體透過雲端託管服務或行動應用程式部署，而泵浦則提供貼片式或管式兩種版本，以滿足不同使用者的偏好。胰島素類型的選擇－從速效胰島素（如Aspart、Glulisine和Lispro）到超速效胰島素（如常規U100、Fiasp和Lymijev）－會影響動態動力學與控制演算法和餐後血糖值的匹配。

技術模式，例如藍牙（新型 BLE 5.0 或傳統 BLE 變體）、行動電話連接和 Wi-Fi 選項（在 2.4 GHz 或 5 GHz 頻段運行），決定了遠端監控、韌體更新頻率和網路安全考量。糖尿病類型對於臨床定位至關重要。孕婦患者群體表現出獨特的安全閾值，1 型隊列細分為早發性和晚發性自體免疫表現，2 型組分為胰島素依賴性和非胰島素依賴性類別，具有不同的支持需求。從普通病房和加護病房等住院環境到門診日托和專科中心等門診診所，護理環境決定了通訊協定複雜性和設備監控水平。最終用戶包括門診服務、診所、成人和兒科居家照護機構以及醫院，包括門診手術中心和住院部。分銷管道分為線下和線上藥房途徑，這會影響訪問、報銷和病患教育模式。

結合這些細分維度，可以明確漸進式創新將在哪些方面帶來最大的臨床和商業性投資回報率，以及整合、監管協調和人為因素工程需要優先關注的地方。

細緻入微的區域見解概述了報銷系統、法律規範、供應鏈現實和文化因素如何影響全球主要地區自動胰島素輸送的採用

區域動態持續影響全球主要市場自動化胰島素給藥系統的採用路徑、報銷模式和監管方式，而私人和公共採購機制則影響通路策略以及資本支持模式和服務型模式之間的平衡。從美洲到歐洲、中東和非洲，監管協調工作和國家衛生技術評估框架決定了採用路徑的差異。在這些地區，互通性和資料管治正成為跨境資料共用和多中心部署的核心考量。

亞太市場競爭激烈，既有機會，也有實施挑戰，包括快速的都市化、糖尿病盛行率的上升以及不斷發展的數位健康生態系統。本地製造能力和區域供應鏈政策影響設備的可用性和成本結構，而文化因素和衛生系統組織則影響病患教育、設備接受度和醫療服務模式。在任何地區，當地監管政策、報銷環境和醫療保健基礎設施的相互作用決定了哪種商業性模式（直接面向患者、藥房合作或醫院採購）最為有效。這要求區域領導者根據每個國家的報銷重點、醫療保健提供者培訓途徑和患者支援需求，制定量身定做的打入市場策略。

主要企業層面訊息，解釋策略夥伴關係、互通性、臨床檢驗和垂直整合如何塑造競爭定位和長期差異化

自動化胰島素輸送領域的公司正透過平台整合、軟體創新和策略夥伴關係關係等多種方式脫穎而出。市場領導優先考慮互通性，建立生態系統，使感測器、泵浦和演算法軟體能夠無縫通訊，並透過無線更新和數據主導的最佳化來適應不斷變化的用戶需求。同時，新參與企業則專注於利基價值提案，例如簡化的貼片式泵浦、高精度感測器化學或演算法個性化，以佔領尚未充分服務的細分市場。

從組件供應協議到與學術中心和醫療系統的臨床合作，夥伴關係策略正在加速檢驗週期和應用。由於數位化能力如今已成為關鍵的績效屬性，對網路安全、資料隱私和法規合規性的投資已成為競爭的必要條件。能夠確保強力的臨床證據、可靠的真實世界結果以及與電子健康記錄高效整合的組織，更有可能實現持續的差異化。此外，從胰島素配方合作到設備製造再到軟體和服務的垂直整合，可以減少對外部供應商的依賴，並更好地掌控使用者體驗。

在這種不斷變化的環境中，那些能夠平衡產品卓越性、營運彈性、證據生成和以客戶為中心的服務模式的公司將最有能力獲得長期臨床和商業性價值。

旨在幫助製造商、付款人和衛生系統加強胰島素自動注射器的供應彈性、臨床證據、使用者體驗和商業模式的可行建議

產業領導者可以採取實際措施，確保競爭優勢，加速應用，並降低整個自動化胰島素輸送價值鏈的營運風險。首先，透過策略多元化、區域供應商資格認證以及關鍵零件的雙重採購來增強供應鏈的韌性，可以降低貿易政策衝擊和生產中斷的風險。其次，優先採用模組化產品設計，使感測器、幫浦和軟體元件能夠互通，從而降低監管複雜性，並縮短漸進式改進的上市時間。

第三，投資於產生嚴格的臨床證據，包括在不同人群和護理環境中進行的真實世界研究，將建立付款人的信任並支持報銷討論。第四，透過人為因素調查、簡化的入職培訓和有針對性的教育計劃改善使用者體驗，將提高依從性和臨床結果，特別是在兒科和老年群體中。第五，採用透明的數據管治、強大的網路安全措施和清晰的演算法更新路徑，將在滿足監管期望的同時培養臨床醫生和患者的信任。最後，探索靈活的商業模式，例如配套服務產品、軟體更新的訂閱計劃和藥房分銷合作夥伴關係，可以使感知價值與價格保持一致並擴大可及性。透過以綜合方式實施這些建議，組織可以使臨床優先事項與商業性現實和長期永續性保持一致。

一種多方法調查方法，整合了臨床醫生訪談、監管審查、技術分析和情境映射，以透明地檢驗敘述見解並確保可重複性

本執行摘要所依據的研究採用了多種方法，旨在捕捉與自動胰島素輸送系統相關的技術、臨床、監管和商業動態。主要的定性輸入包括對內分泌科和急診護理臨床醫生、醫院和診所採購負責人、設備技術人員以及患者權益倡導者的結構化訪談，以發現可用性方面的考慮因素和採用障礙。二級資訊來源包括同行評審的臨床文獻、監管指南文件、專利申請和技術白皮書，以描述技術發展軌跡和安全考慮。

分析方法包括將產品特性集與臨床用例進行交叉映射，情境分析以探索供應鍊和政策風險，以及將訪談結果與已發表的證據進行三角檢驗以檢驗主題見解。我們仔細區分了硬體主導的限制和軟體主導的機會，並記錄了當地監管的細微差別。品質保證流程包括來源檢驗、專家同行評審和敏感性檢查，以確保結論反映的是穩健的、趨同的證據，而非單一來源的假設。此調查方法優先考慮透明度和可重複性，同時也認知到一些局限性，例如快速變化的監管決策和可能影響產品層面解讀的獨特數據缺口。

全面討論簡明結論，整合技術進步、臨床重點、區域動態和業務需求，以指南策略決策

摘要：自動化胰島素輸送系統正處於技術創新、臨床轉化和商業性動態轉變的十字路口。感測器精度的提升、控制演算法的多樣化以及泵浦外形規格的改進正在共同作用，以提供更多以患者為中心的解決方案。 2025年的關稅環境重新定義了採購和尋源的優先級，推動主要企業走向區域化、模組化和軟體主導的差異化。

對於相關人員，未來的挑戰顯而易見：投資可互通的架構，在不同人群和護理環境中產生可靠的臨床證據，並設計兼顧現實世界依從性挑戰的使用者體驗。同時，各機構必須增強供應鏈的韌性，並尋求切實可行的商業模式，以協調病患、醫療服務提供者和付款人的獎勵。透過將卓越技術與實證部署和彈性運作相結合，自動化胰島素給藥生態系統能夠在持續創新的同時，擴大可及性並改善患者預後。

目錄

第1章 引言

第2章分析方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 將連續血糖監測數據與自適應胰島素劑量演算法結合，以改善血糖控制
  • 智慧型手機連接實現遠端用戶監控和即時胰島素調整
  • 採用混合閉合迴路系統，根據預測分析提供個人化胰島素劑量
  • 監管部門的核准將加速與多種 CGM 設備相容的可互通胰島素幫浦的使用
  • 開發結合胰島素和升糖素的雙重荷爾蒙傳遞系統，以增強低血糖預防
  • 新興的基於人工智慧的決策支援工具，用於最佳化閉合迴路治療中的基礎和Bolus胰島素劑量
  • 我們專注於緊湊、穿戴式的外形，以提高自動輸送系統中的使用者舒適度和謹慎性。

第6章：美國關稅的累積影響（2025年）

第7章：人工智慧（AI）的累積影響（2025年）

8. 自動胰島素輸送系統市場（依產品類型）

  • 完全閉合迴路
  • 混合閉合迴路
    • 模糊邏輯
    • 模型預測控制
    • 比例積分導數
  • 感測器膨脹泵
  • 閾值懸掛泵

9. 自動胰島素輸送系統市場（按組件）

  • 連續血糖監測儀
    • 快閃記憶體監控
    • 即時的
  • 控制演算法軟體
    • 雲端基礎
    • 基於行動裝置
  • 泵浦
    • 貼片幫浦
    • 管泵

第 10 章。自動胰島素輸送系統市場（按胰島素類型）

  • 快速起效
    • Aspart
    • Glulisine
    • Lispro
  • 常規 U100
  • 超快
    • 恐懼
    • 雷姆熱夫

11. 自動胰島素輸送系統市場（依技術）

  • 基於藍牙
    • BLE 5.0
    • 傳統 BLE
  • 基於蜂巢
  • 基於Wi-Fi
    • 2.4GHz頻段
    • 5GHz頻段

第 12 章。以糖尿病類型分類的自動胰島素輸送系統市場

  • 妊娠糖尿病
  • 1型糖尿病
    • 早發
    • 晚期自體免疫疾病
  • 2型糖尿病
    • 胰島素依賴型
    • 非胰島素依賴型

13. 自動胰島素輸送系統市場（依治療環境）

  • 住院病人
    • 普通病房
    • 加護病房
  • 門診
    • 門診日間護理
    • 專科診所

第 14 章。自動胰島素輸送系統市場（按最終用戶）

  • 門診
  • 診所
  • 居家醫療
    • 成人用戶
    • 兒科用戶
  • 醫院
    • 門診手術中心
    • 住院病人

15. 自動胰島素輸送系統市場（依分銷管道）

  • 線下藥局
  • 網路藥局

16. 自動胰島素輸送系統市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 17 章。自動胰島素輸送系統市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

18. 自動胰島素輸送系統市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第19章 競爭態勢

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Medtronic plc
    • Tandem Diabetes Care, Inc.
    • Insulet Corporation
    • F. Hoffmann-La Roche Ltd
    • Beta Bionics, Inc.
    • Bigfoot Biomedical, Inc.
    • Ypsomed AG
    • Diabeloop SAS
    • Sooil Development Co., Ltd.
    • DreaMed Diabetes Ltd.
Product Code: MRR-437517DB6E7D

The Automated Insulin Delivery System Market is projected to grow by USD 1,942.07 million at a CAGR of 10.07% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 901.04 million
Estimated Year [2025] USD 990.29 million
Forecast Year [2032] USD 1,942.07 million
CAGR (%) 10.07%

A comprehensive introduction outlining how integrated sensing, advanced control algorithms, and device ergonomics are redefining clinical and commercial expectations for automated insulin delivery

Automated insulin delivery systems are reshaping diabetes management by integrating continuous glucose sensing, adaptive control algorithms, and automated insulin delivery to reduce day-to-day burden and improve glycemic stability. Recent device generations have moved beyond component-level improvements to a systems-level approach, where sensor fidelity, algorithm sophistication, and pump ergonomics converge to create closed-loop experiences that respond dynamically to physiologic variability. This trajectory reflects decades of incremental innovation combined with accelerated digital health adoption.

Clinicians and health systems increasingly evaluate these platforms not solely on isolated metrics but on how they affect patient-centered outcomes, workflow integration, and long-term adherence. Meanwhile, software-driven control strategy advances enable smoother glycemic trajectories and richer telehealth-enabled touchpoints. As a result, product differentiation has shifted toward interoperability, user experience design, and data security rather than mechanical actuator performance alone.

Taken together, these developments have expanded the dialogue around automated delivery from a purely engineering challenge to a multidisciplinary implementation task. Stakeholders must therefore consider clinical protocols, reimbursement pathways, patient education, and the evolving regulatory environment as core elements of any deployment strategy.

An in-depth exploration of the converging technological, regulatory, and user-experience forces that are driving accelerated evolution across the automated insulin delivery landscape

The landscape for automated insulin delivery is experiencing transformative shifts driven by converging technological, clinical, and commercial forces. Advancements in continuous glucose monitoring have improved signal stability and reduced lag time, enabling control algorithms to make more reliable dosing decisions. At the same time, algorithmic approaches have diversified from rule-based heuristics to predictive and adaptive models that incorporate variability in meal behavior, exercise, and stress responses. This evolution enhances safety margins while also enabling personalization at the individual patient level.

On the commercial side, user experience design and form-factor innovation are increasing adoption by addressing adherence barriers such as device visibility, insertion discomfort, and device maintenance burden. Interoperability frameworks and open protocol initiatives are encouraging modular ecosystems in which pumps, sensors, and software can be combined in new configurations. Concurrently, regulatory agencies are developing clearer pathways for software and algorithm updates, which supports iterative improvement cycles after initial approval. These shifts collectively move the field from siloed product launches toward ecosystem orchestration where clinical outcomes, patient satisfaction, and operational integration determine long-term success.

A strategic examination of the cumulative operational and supply chain consequences stemming from the United States tariff regime introduced in 2025 and how stakeholders can adapt

The imposition of new tariffs and trade policies in the United States in 2025 has created tangible operational and strategic implications for manufacturers, distributors, and healthcare purchasers involved with automated insulin delivery systems. While tariffs typically manifest as increased landed costs for hardware components and finished devices, their broader effects can cascade through supply chain design, sourcing decisions, and product roadmaps. Organizations with lean, geographically concentrated supply chains are more exposed to cost volatility, whereas those with diversified procurement strategies can preserve margin and maintain pricing flexibility.

From a sourcing perspective, tariffs incentivize nearshoring and suppliers' regionalization, especially for critical components such as sensor materials, semiconductor chips used in control electronics, and specialized pump actuators. This shift alters supplier negotiation dynamics and may accelerate investments in local manufacturing capacity, certification, and quality assurance processes. Regulatory and procurement teams must also anticipate changes in vendor evaluation criteria, including total landed cost, lead-time reliability, and resilience to future trade policy shifts.

Clinicians and health systems may experience slower product refresh cycles in some segments if manufacturers defer non-essential launches to manage cost pressures. At the same time, software-centric features that require fewer physical inputs can gain relative prominence as a cost-effective way to differentiate offerings. Overall, the tariff environment reframes strategic priorities toward supply chain resilience, modular product architectures, and collaborations that mitigate exposure to trade disruptions.

Comprehensive segmentation-driven insights that connect product architectures, component choices, insulin formulations, connectivity standards, care contexts, and distribution strategies into actionable commercial intelligence

Insightful segmentation reveals how product design choices and end-use contexts shape clinical value propositions and commercialization strategies for automated insulin delivery systems. Based on product type, platforms vary from fully closed loop systems that aim to minimize manual input to hybrid closed loop configurations that blend automated basal adjustments with user-led boluses; within hybrid solutions, control approaches span fuzzy logic, model predictive control, and proportional integral derivative techniques, each delivering different trade-offs between responsiveness and stability. Sensor-augmented pumps and threshold suspend pumps remain relevant in specific clinical niches where cost, familiarity, or regulatory constraints influence selection.

Component-level distinctions further define capability and integration pathways. Continuous glucose monitors provide either flash monitoring or real-time telemetry, control algorithm software may be deployed via cloud-hosted services or mobile-based applications, and pumps appear as patch or tubed variants that appeal to divergent user preferences. Insulin type selection-from rapid-acting agents such as aspart, glulisine, and lispro to regular U100 and ultra-rapid formulations like Fiasp and Lyumjev-affects pharmacodynamic matching with control algorithms and post-prandial glycemic outcomes.

Technology modalities including Bluetooth implementations (with newer BLE 5.0 or legacy BLE variants), cellular connectivity, and WiFi options (operating on 2.4 GHz or 5 GHz bands) shape remote monitoring, firmware update cadence, and cybersecurity considerations. Diabetes type matters to clinical targeting: gestational populations present unique safety thresholds, Type 1 cohorts subdivide into juvenile onset and late autoimmune presentations, and Type 2 groups separate into insulin-dependent and non-insulin-dependent categories with differing support needs. Care settings-ranging from inpatient environments like general wards and intensive care units to outpatient clinics such as ambulatory daycare and specialty centers-define protocol complexity and device oversight levels. End users include ambulatory services, clinics, homecare environments with adult and pediatric distinctions, and hospitals encompassing ambulatory surgical centers and inpatient units, while distribution channels split between offline pharmacy and online pharmacy routes that influence access, reimbursement, and patient education models.

Together, these segmentation axes clarify where incremental innovation will yield the most clinical and commercial ROI, and where integration, regulatory alignment, and human factors engineering demand priority attention.

Regionally nuanced insights outlining how reimbursement systems, regulatory frameworks, supply chain realities, and cultural factors influence automated insulin delivery penetration across major global regions

Regional dynamics continue to shape adoption pathways, reimbursement models, and regulatory approaches for automated insulin delivery systems across major global markets. In the Americas, clinical practice patterns and payer structures drive demand for integrated solutions that demonstrate clear improvements in patient outcomes and resource utilization; meanwhile, private and public procurement mechanisms influence channel strategies and the balance between capital procurement and service-based models. Transitioning from the Americas to Europe, Middle East & Africa, regulatory harmonization efforts and national health technology assessment frameworks create differentiated pathways to adoption, where local clinical guidelines and reimbursement thresholds affect the timing and breadth of coverage. In these regions, interoperability and data governance emerge as central considerations for cross-border data sharing and multisite deployments.

Asia-Pacific markets present a heterogeneous landscape, where rapid urbanization, expanding diabetes prevalence, and growing digital health ecosystems create both opportunities and implementation challenges. Local manufacturing capacity and regional supply chain policies influence device availability and cost structures, while cultural factors and health system organization impact patient education, device acceptance, and care delivery models. Across all regions, the interplay between local regulatory policy, reimbursement environments, and healthcare infrastructure determines which commercial approaches-direct-to-patient distribution, pharmacy partnerships, or hospital procurement-will be most effective. Regional leaders thus need tailored go-to-market strategies that align with national reimbursement priorities, provider training pathways, and patient support needs.

Key company-level intelligence describing how strategic partnerships, interoperability, clinical validation, and vertical integration are shaping competitive positioning and long-term differentiation

Companies operating in the automated insulin delivery space are increasingly differentiating through a mix of platform integration, software innovation, and strategic partnerships. Market leaders prioritize interoperability, building ecosystems in which sensors, pumps, and algorithm software can communicate seamlessly and adapt to users' changing needs through over-the-air updates and data-driven optimization. At the same time, new entrants focus on niche value propositions such as simplified patch-based pumps, highly accurate sensor chemistries, or algorithmic personalization to capture underserved segments.

Partnership strategies range from component supply agreements to clinical collaborations with academic centers and health systems, accelerating validation cycles and adoption. Investment in cybersecurity, data privacy, and regulatory compliance has become a competitive imperative because digital features now represent critical performance attributes. Organizations that secure strong clinical evidence, robust real-world outcomes, and streamlined integration with electronic health records will achieve durable differentiation. Moreover, vertical integration-spanning from insulin formulation partnerships to device manufacturing and software services-can reduce dependency on external suppliers and enable tighter control over user experience, although it requires substantial capital and cross-disciplinary capabilities.

In this evolving environment, companies that balance product excellence with operational resilience, evidence generation, and customer-centric service models are best positioned to capture long-term clinical and commercial value.

Actionable recommendations aimed at helping manufacturers, payers, and health systems strengthen supply resilience, clinical evidence, user experience, and commercial models for automated insulin delivery

Industry leaders can take concrete steps to secure competitive advantage, accelerate adoption, and mitigate operational risks across the automated insulin delivery value chain. First, strengthening supply chain resilience through strategic diversification, regional supplier qualification, and dual-sourcing of critical components reduces exposure to trade policy shocks and manufacturing disruptions. Second, prioritizing modular product designs that allow sensor, pump, and software components to interoperate eases regulatory complexity and shortens time-to-market for incremental improvements.

Third, investing in rigorous clinical evidence generation-including real-world studies across diverse populations and care settings-builds payer confidence and supports reimbursement discussions. Fourth, enhancing user experience through human factors research, simplified onboarding, and targeted education programs improves adherence and clinical outcomes, particularly among pediatric and geriatric cohorts. Fifth, embracing transparent data governance, robust cybersecurity measures, and clear update pathways for algorithms fosters trust among clinicians and patients while meeting regulatory expectations. Finally, exploring flexible commercial models, such as bundled service offerings, subscription plans for software updates, and pharmacy partnerships for distribution, can align pricing with perceived value and expand access. Implementing these recommendations in an integrated manner will help organizations reconcile clinical priorities with commercial realities and long-term sustainability.

Transparent explanation of the multi-method research approach integrating clinician interviews, regulatory review, technical analysis, and scenario mapping to validate insights and ensure reproducibility

The research underpinning this executive summary employed a multi-method approach designed to capture technology, clinical, regulatory, and commercial dynamics relevant to automated insulin delivery systems. Primary qualitative inputs included structured interviews with clinicians across endocrinology and acute care, procurement leads from hospitals and clinics, device engineers, and patient advocates to surface usability considerations and adoption barriers. Secondary sources comprised peer-reviewed clinical literature, regulatory guidance documents, patent filings, and technical white papers to characterize technological trajectories and safety considerations.

Analytical methods included cross-sectional mapping of product feature sets against clinical use cases, scenario analyses to explore supply chain and policy risks, and triangulation of interview findings with published evidence to validate thematic insights. Attention was given to distinguishing between hardware-driven constraints and software-enabled opportunities, as well as to documenting regional regulatory nuances. Quality assurance processes encompassed source verification, expert peer review, and sensitivity checks to ensure that conclusions reflect robust convergent evidence rather than single-source assumptions. The methodology prioritized transparency and reproducibility while acknowledging limits such as rapidly evolving regulatory decisions and proprietary data gaps that can affect granular product-level interpretation.

A concise concluding synthesis that integrates technological progress, clinical priorities, regional dynamics, and operational imperatives to guide strategic decision-making

In summary, automated insulin delivery systems stand at the intersection of technological innovation, clinical practice transformation, and shifting commercial dynamics. Improvements in sensor accuracy, diversified control algorithms, and refined pump form factors are converging to deliver more patient-centric solutions, while regional policy, reimbursement, and supply chain realities continue to shape adoption pathways. The 2025 tariff environment reframed procurement and sourcing priorities, nudging companies toward regionalization, modularity, and software-led differentiation.

For stakeholders, the immediate imperatives are clear: invest in interoperable architectures, generate robust clinical evidence across diverse populations and care settings, and design user experiences that account for real-world adherence challenges. At the same time, organizations must bolster supply chain resilience and pursue pragmatic commercial models that align incentives across patients, providers, and payers. By integrating technical excellence with evidence-driven deployment and resilient operations, the automated insulin delivery ecosystem can sustain innovation while expanding access and improving patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of continuous glucose monitoring data with adaptive insulin dosing algorithms to improve glycemic control
  • 5.2. Implementation of smartphone connectivity to allow remote monitoring and real time insulin adjustments for users
  • 5.3. Adoption of hybrid closed loop systems offering personalized insulin delivery based on predictive analytics
  • 5.4. Regulatory approvals driving the availability of interoperable insulin pumps compatible with multiple CGM devices
  • 5.5. Development of dual hormone delivery systems combining insulin and glucagon for enhanced hypoglycemia prevention
  • 5.6. Emergence of AI based decision support tools for optimizing basal and bolus insulin rates in closed loop therapy
  • 5.7. Focus on compact wearable form factors to enhance user comfort and discreetness in automated delivery systems

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Automated Insulin Delivery System Market, by Product Type

  • 8.1. Fully Closed Loop
  • 8.2. Hybrid Closed Loop
    • 8.2.1. Fuzzy Logic
    • 8.2.2. Model Predictive Control
    • 8.2.3. Proportional Integral Derivative
  • 8.3. Sensor Augmented Pump
  • 8.4. Threshold Suspend Pump

9. Automated Insulin Delivery System Market, by Component

  • 9.1. Continuous Glucose Monitor
    • 9.1.1. Flash Monitoring
    • 9.1.2. Real Time
  • 9.2. Control Algorithm Software
    • 9.2.1. Cloud Based
    • 9.2.2. Mobile Based
  • 9.3. Pump
    • 9.3.1. Patch Pump
    • 9.3.2. Tubed Pump

10. Automated Insulin Delivery System Market, by Insulin Type

  • 10.1. Rapid Acting
    • 10.1.1. Aspart
    • 10.1.2. Glulisine
    • 10.1.3. Lispro
  • 10.2. Regular U100
  • 10.3. Ultra Rapid
    • 10.3.1. Fiasp
    • 10.3.2. Lyumjev

11. Automated Insulin Delivery System Market, by Technology

  • 11.1. Bluetooth Based
    • 11.1.1. BLE 5.0
    • 11.1.2. Legacy BLE
  • 11.2. Cellular Based
  • 11.3. WiFi Based
    • 11.3.1. 2.4 GHz
    • 11.3.2. 5 GHz

12. Automated Insulin Delivery System Market, by Diabetes Type

  • 12.1. Gestational
  • 12.2. Type 1
    • 12.2.1. Juvenile Onset
    • 12.2.2. Late Autoimmune
  • 12.3. Type 2
    • 12.3.1. Insulin Dependent
    • 12.3.2. Non Insulin Dependent

13. Automated Insulin Delivery System Market, by Care Setting

  • 13.1. Inpatient
    • 13.1.1. General Ward
    • 13.1.2. Intensive Care Unit
  • 13.2. Outpatient
    • 13.2.1. Ambulatory Daycare
    • 13.2.2. Specialty Clinic

14. Automated Insulin Delivery System Market, by End User

  • 14.1. Ambulatory
  • 14.2. Clinics
  • 14.3. Homecare
    • 14.3.1. Adult Users
    • 14.3.2. Pediatric Users
  • 14.4. Hospital
    • 14.4.1. Ambulatory Surgical Centers
    • 14.4.2. Inpatient

15. Automated Insulin Delivery System Market, by Distribution Channel

  • 15.1. Offline Pharmacy
  • 15.2. Online Pharmacy

16. Automated Insulin Delivery System Market, by Region

  • 16.1. Americas
    • 16.1.1. North America
    • 16.1.2. Latin America
  • 16.2. Europe, Middle East & Africa
    • 16.2.1. Europe
    • 16.2.2. Middle East
    • 16.2.3. Africa
  • 16.3. Asia-Pacific

17. Automated Insulin Delivery System Market, by Group

  • 17.1. ASEAN
  • 17.2. GCC
  • 17.3. European Union
  • 17.4. BRICS
  • 17.5. G7
  • 17.6. NATO

18. Automated Insulin Delivery System Market, by Country

  • 18.1. United States
  • 18.2. Canada
  • 18.3. Mexico
  • 18.4. Brazil
  • 18.5. United Kingdom
  • 18.6. Germany
  • 18.7. France
  • 18.8. Russia
  • 18.9. Italy
  • 18.10. Spain
  • 18.11. China
  • 18.12. India
  • 18.13. Japan
  • 18.14. Australia
  • 18.15. South Korea

19. Competitive Landscape

  • 19.1. Market Share Analysis, 2024
  • 19.2. FPNV Positioning Matrix, 2024
  • 19.3. Competitive Analysis
    • 19.3.1. Medtronic plc
    • 19.3.2. Tandem Diabetes Care, Inc.
    • 19.3.3. Insulet Corporation
    • 19.3.4. F. Hoffmann-La Roche Ltd
    • 19.3.5. Beta Bionics, Inc.
    • 19.3.6. Bigfoot Biomedical, Inc.
    • 19.3.7. Ypsomed AG
    • 19.3.8. Diabeloop SAS
    • 19.3.9. Sooil Development Co., Ltd.
    • 19.3.10. DreaMed Diabetes Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INSULIN TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INSULIN TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DIABETES TYPE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DIABETES TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CARE SETTING, 2024 VS 2032 (%)
  • FIGURE 13. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CARE SETTING, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 15. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 17. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AMERICAS AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. NORTH AMERICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. LATIN AMERICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. EUROPE AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. MIDDLE EAST AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. AFRICA AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. ASIA-PACIFIC AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. ASEAN AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. GCC AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 30. EUROPEAN UNION AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 31. BRICS AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 32. G7 AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 33. NATO AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 34. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 35. AUTOMATED INSULIN DELIVERY SYSTEM MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 36. AUTOMATED INSULIN DELIVERY SYSTEM MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AUTOMATED INSULIN DELIVERY SYSTEM MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PRODUCT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FULLY CLOSED LOOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FULLY CLOSED LOOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FULLY CLOSED LOOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FULLY CLOSED LOOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FULLY CLOSED LOOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FULLY CLOSED LOOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY HYBRID CLOSED LOOP, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY HYBRID CLOSED LOOP, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY HYBRID CLOSED LOOP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY HYBRID CLOSED LOOP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY HYBRID CLOSED LOOP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY HYBRID CLOSED LOOP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY HYBRID CLOSED LOOP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY HYBRID CLOSED LOOP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FUZZY LOGIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FUZZY LOGIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FUZZY LOGIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FUZZY LOGIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FUZZY LOGIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FUZZY LOGIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MODEL PREDICTIVE CONTROL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MODEL PREDICTIVE CONTROL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MODEL PREDICTIVE CONTROL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MODEL PREDICTIVE CONTROL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MODEL PREDICTIVE CONTROL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MODEL PREDICTIVE CONTROL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PROPORTIONAL INTEGRAL DERIVATIVE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PROPORTIONAL INTEGRAL DERIVATIVE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PROPORTIONAL INTEGRAL DERIVATIVE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PROPORTIONAL INTEGRAL DERIVATIVE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PROPORTIONAL INTEGRAL DERIVATIVE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PROPORTIONAL INTEGRAL DERIVATIVE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY SENSOR AUGMENTED PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY SENSOR AUGMENTED PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY SENSOR AUGMENTED PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY SENSOR AUGMENTED PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY SENSOR AUGMENTED PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY SENSOR AUGMENTED PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY THRESHOLD SUSPEND PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY THRESHOLD SUSPEND PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY THRESHOLD SUSPEND PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY THRESHOLD SUSPEND PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY THRESHOLD SUSPEND PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY THRESHOLD SUSPEND PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY COMPONENT, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTINUOUS GLUCOSE MONITOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FLASH MONITORING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FLASH MONITORING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FLASH MONITORING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FLASH MONITORING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FLASH MONITORING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FLASH MONITORING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REAL TIME, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REAL TIME, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REAL TIME, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REAL TIME, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REAL TIME, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REAL TIME, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTROL ALGORITHM SOFTWARE, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTROL ALGORITHM SOFTWARE, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTROL ALGORITHM SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTROL ALGORITHM SOFTWARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTROL ALGORITHM SOFTWARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTROL ALGORITHM SOFTWARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTROL ALGORITHM SOFTWARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CONTROL ALGORITHM SOFTWARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CLOUD BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CLOUD BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CLOUD BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CLOUD BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CLOUD BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MOBILE BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MOBILE BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MOBILE BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MOBILE BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MOBILE BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY MOBILE BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PUMP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PUMP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PATCH PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PATCH PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PATCH PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PATCH PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PATCH PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY PATCH PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TUBED PUMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TUBED PUMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TUBED PUMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TUBED PUMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TUBED PUMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TUBED PUMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INSULIN TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INSULIN TYPE, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY RAPID ACTING, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY RAPID ACTING, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY RAPID ACTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY RAPID ACTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY RAPID ACTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY RAPID ACTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY RAPID ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ASPART, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ASPART, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ASPART, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ASPART, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ASPART, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ASPART, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GLULISINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GLULISINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GLULISINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GLULISINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GLULISINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GLULISINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LISPRO, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LISPRO, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LISPRO, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LISPRO, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LISPRO, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LISPRO, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REGULAR U100, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REGULAR U100, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REGULAR U100, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REGULAR U100, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REGULAR U100, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY REGULAR U100, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ULTRA RAPID, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ULTRA RAPID, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ULTRA RAPID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ULTRA RAPID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ULTRA RAPID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ULTRA RAPID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ULTRA RAPID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY ULTRA RAPID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FIASP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FIASP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FIASP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FIASP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FIASP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY FIASP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LYUMJEV, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LYUMJEV, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LYUMJEV, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LYUMJEV, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LYUMJEV, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LYUMJEV, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLUETOOTH BASED, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLUETOOTH BASED, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLUETOOTH BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLUETOOTH BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLUETOOTH BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLUETOOTH BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLUETOOTH BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLUETOOTH BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLE 5.0, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLE 5.0, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLE 5.0, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLE 5.0, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLE 5.0, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY BLE 5.0, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LEGACY BLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LEGACY BLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LEGACY BLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LEGACY BLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LEGACY BLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LEGACY BLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CELLULAR BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CELLULAR BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CELLULAR BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CELLULAR BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CELLULAR BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CELLULAR BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY WIFI BASED, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY WIFI BASED, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY WIFI BASED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY WIFI BASED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY WIFI BASED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY WIFI BASED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY WIFI BASED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY WIFI BASED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 2.4 GHZ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 2.4 GHZ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 2.4 GHZ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 2.4 GHZ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 2.4 GHZ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 2.4 GHZ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 5 GHZ, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 5 GHZ, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 5 GHZ, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 5 GHZ, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 5 GHZ, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY 5 GHZ, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GESTATIONAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GESTATIONAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GESTATIONAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GESTATIONAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GESTATIONAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GESTATIONAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 1, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 1, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 1, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 1, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 1, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 1, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 1, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 1, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY JUVENILE ONSET, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY JUVENILE ONSET, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY JUVENILE ONSET, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY JUVENILE ONSET, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY JUVENILE ONSET, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY JUVENILE ONSET, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LATE AUTOIMMUNE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LATE AUTOIMMUNE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LATE AUTOIMMUNE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LATE AUTOIMMUNE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LATE AUTOIMMUNE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY LATE AUTOIMMUNE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 2, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 2, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 2, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 2, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 2, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 2, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 2, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY TYPE 2, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INSULIN DEPENDENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INSULIN DEPENDENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INSULIN DEPENDENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INSULIN DEPENDENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INSULIN DEPENDENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INSULIN DEPENDENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY NON INSULIN DEPENDENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY NON INSULIN DEPENDENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY NON INSULIN DEPENDENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY NON INSULIN DEPENDENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY NON INSULIN DEPENDENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY NON INSULIN DEPENDENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CARE SETTING, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY CARE SETTING, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INPATIENT, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INPATIENT, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INPATIENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INPATIENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INPATIENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INPATIENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INPATIENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INPATIENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GENERAL WARD, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GENERAL WARD, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GENERAL WARD, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GENERAL WARD, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY GENERAL WARD, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 280. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INTENSIVE CARE UNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 281. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 282. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INTENSIVE CARE UNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 283. GLOBAL AUTOMATED INSULIN DELIVERY SYSTEM MARKET SIZE, BY INTENSIVE CARE UNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 284. GLOBAL AUTOMATED I